Gerard Fernando, MD
Psychiatry · Bakersfield, CANPI 1750645024
Payments from drug & device makers
Across 554 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- Lundbeck LLC$1K
- Alkermes, Inc.$949
- Supernus Pharmaceuticals, Inc.$748
- Takeda Pharmaceuticals U.S.A., Inc.$720
- Johnson & Johnson$689
- plus $4K from 29 others
What the payments were for
- Food & beverage$9,43296%
- Education$4354%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 70 | $1,492 |
| Lundbeck LLC | 71 | $1,044 |
| Alkermes, Inc. | 73 | $949 |
| Supernus Pharmaceuticals, Inc. | 40 | $748 |
| Takeda Pharmaceuticals U.S.A., Inc. | 52 | $720 |
| Johnson & Johnson | 39 | $689 |
| Otsuka America Pharmaceutical, Inc. | 34 | $682 |
| AbbVie(2 entities) | 40 | $660 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 20 | $494 |
| Indivior Inc. | 24 | $477 |
| Neurocrine Biosciences, Inc. | 16 | $426 |
| Sunovion Pharmaceuticals Inc. | 13 | $194 |
| Vanda Pharmaceuticals Inc. | 9 | $168 |
| E.r. Squibb & Sons, L.L.C. | 8 | $150 |
| Ironshore Pharmaceuticals Inc. | 7 | $123 |
| Orapharma, A Division Of Bausch Health US, LLC | 1 | $88 |
| Tris Pharma Inc | 5 | $84 |
| Axsome Therapeutics, Inc. | 3 | $69 |
| Bausch Health US, LLC | 3 | $68 |
| Harmony Biosciences LLC | 2 | $67 |
| Almatica Pharma LLC | 3 | $64 |
| Noven Therapeutics, LLC | 3 | $51 |
| Collegium Pharmaceutical, Inc. | 2 | $49 |
| Idorsia Pharmaceuticals US Inc | 2 | $40 |
| Merck | 2 | $35 |
| Sage Therapeutics, LLC | 1 | $35 |
| Neuronetics, Inc. | 1 | $33 |
| Bioxcel Therapeutics, Inc. | 2 | $30 |
| Braeburn Inc. | 1 | $25 |
| Corium, LLC | 2 | $25 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| USWM, LLC | 1 | $17 |
| Shire North American Group Inc | 1 | $17 |
| Eisai Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$120
How this compares
$9,867 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 32 | $296,004 |
| Austedo XrDeutetrabenazine | 19 | $142,468 |
| RexultiBrexpiprazole | 87 | $130,073 |
| Abilify MaintenaAripiprazole | 32 | $91,934 |
| CaplytaLumateperone Tosylate | 43 | $69,409 |
| VraylarCariprazine Hcl | 39 | $54,625 |
| TrintellixVortioxetine Hydrobromide | 76 | $43,364 |
| LybalviOlanzapine/Samidorphan Malate | 16 | $24,295 |
| Lurasidone Hcl | 76 | $22,985 |
| SublocadeBuprenorphine | 11 | $21,335 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 156 | $16,677 |
| VyvanseLisdexamfetamine Dimesylate | 36 | $13,842 |
| Atomoxetine Hcl | 133 | $13,526 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $11,818 |
| Aripiprazole | 145 | $11,112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $426 | $296,00432 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $682 | $222,007119 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,492 | $142,46819 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $494 | $69,40943 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $720 | $57,206112 claims |
| AbbVieVraylar | $660 | $54,62539 claims |
| Alkermes, Inc.Lybalvi | $949 | $24,29516 claims |
| Indivior Inc.Sublocade | $477 | $21,33511 claims |
| Axsome Therapeutics, Inc.Auvelity | $69 | $11,81812 claims |
| Eisai Inc.Dayvigo | $17 | $5,44217 claims |
| MerckBelsomra | $35 | $4,96012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Bakersfield
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.